Spyre Therapeutics Inc. (SYRE)
Healthcare
Biotechnology
98.30 $
-3.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Spyre Therapeutics Inc. (SYRE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -58 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17 | -35 | -31 | -29 | -62 | -29 | -37 | -41 | -47 | -37 | -45 | -58 | -186 | |
| 0.4 | 0.0 | -0.2 | 0.0 | 0.0 | 0.0 | -11 | – | – | – | -8.1 | – | – | |
| 1.9 | 4.8 | 17 | 14 | 8.7 | 13 | 9.2 | 8.9 | 9.4 | 9.6 | 9.8 | 13 | 42 | |
| 6.0 | -8.0 | -1.9 | 3.5 | -29 | 10 | 11 | -0.6 | -9.0 | 5.9 | -2.3 | 0.2 | -5.1 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 6.8 | -98 | -35 | -105 | -121 | 43 | -171 | -0.1 | 79 | 25 | -247 | 57 | -87 | |
| – | – | – | 0.0 | 0.0 | – | – | -0.1 | 0.0 | – | 0.1 | – | – | |
| – | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | |
| 210 | -13 | 164 | 172 | 0.4 | 13 | 226 | 0.1 | 0.7 | -4.6 | 313 | 12 | 321 | |
| 200 | -145 | 97 | 39 | -182 | 26 | 18 | -41 | 33 | -17 | 21 | 11 | 49 | |
| -17 | -35 | -31 | -29 | -62 | -29 | -37 | -41 | -47 | -37 | -45 | -58 | -186 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.